| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-06-16 | Arena Pharmaceuticals (USA - CA) | resignation |
Resignation | |||
| 2015-06-16 | Medivir (Sweden) GVK Biosciences Private (India) | restructuring |
Cancer - Oncology - Infectious diseases | Restructuring | ||
| 2015-06-15 | Shire (UK-USA) Armagen Technologies (USA - CA) | AGT-182 | Hunter syndrome or mucopolysaccharidosis type II (MPS II) | licensing collaboration |
Rare diseases - Genetic diseases | Milestone |
| 2015-06-15 | Atara Biotherapeutics (USA - CA) Memorial Sloan Kettering Cancer Center (USA - NY) | allogeneic T-cell therapies including T-cells activated against Epstein Barr Virus (EBV), T-cells activated against Cytomegalovirus (CMV) and T-cells activated against Wilms Tumor 1 (WT1) | cancers, viral infections | exercise of an option agreement licensing |
Cancer - Oncology - Infectious diseases | Exercise of an option agreement |
| 2015-06-15 | Agalimmune (UK) KODE Biotech (New Zealand) | KODE™ Technology | licensing | Cancer - Oncology - Technology - Services | Licensing agreement | |
| 2015-06-15 | Bluebird bio (USA - MA) | nomination |
Rare diseases - Genetic diseases - Hematological diseases - Cancer - Oncology | Nomination | ||
| 2015-06-15 | Servier (France) Taiho Pharmaceutical (Japan) | TAS-102 ( trifluridine and tipiracil hydrochloride) | refractory metastatic colorectal cancer | licensing development commercialisation |
Cancer - Oncology | Licensing agreement |
| 2015-06-15 | Plasticell (UK) | nomination |
Technology - Services | Nomination | ||
| 2015-06-15 | PlasmaTech Biopharmaceuticals, now Abeona Therapeutics (USA - NY) University of Minnesota (USA - MN) | ABO-301 (AAV-FANCC) - AAV gene therapy for the treatment of Fanconi anemia | Fanconi anemia | licensing |
Rare diseases - Genetic diseases - Hematological diseases | Licensing agreement |
| 2015-06-12 | Grunenthal (Germany) Proteus (Chile) Boston Children’s Hospital (USA - MA) | neosaxitoxin | local anesthesia, post-operative pain management | collaboration |
CNS diseases | Collaboration agreement |
| 2015-06-11 | Shire (UK - USA) | nomination |
Rare diseases - CNS diseases - Gastrointestinal diseases | Nomination | ||
| 2015-06-11 | Reneuron (UK) | nomination |
Rare diseases - Genetic diseases - Regenerative medicine - Cancer - Oncology | Nomination | ||
| 2015-06-11 | The Lead Discovery Center (LDC) (Germany) Johnson & Johnson Innovation, a J&J company (USA - NJ) | collaboration |
Collaboration agreement | |||
| 2015-06-11 | Seres Therapeutics (USA - MA) | nomination |
Nomination | |||
| 2015-06-11 | RegenXBio (USA - MD) Wuxi Apptec (China) | adeno-associated virus (AAV) gene therapy treatments | manufacturing production |
Rare diseases - Genetic diseases | Production agreement | |
| 2015-06-11 | Bind Therapeutics (USA - MA) Macrophage Therapeutics (USA - OH) | CD206 targeted Accurin nanoparticle | R&D |
Cancer - Oncology | R&D agreement | |
| 2015-06-10 | Medgenics (USA - Israel) | nomination |
Nomination | |||
| 2015-06-10 | Ariad Pharmaceuticals (USA - MA) Paladin Labs (Canada) | Iclusig™ | licensing |
Cancer - Oncology | Licensing agreement | |
| 2015-06-10 | Ariad Pharmaceuticals (USA - MA) Paladin Labs (Canada) | Iclusig™ | licensing |
Cancer - Oncology | Licensing agreement | |
| 2015-06-09 | Tillotts Pharma (Switzerland) Numab AG (Switzerland) | antibody-based therapies against tumor necrosis factor alpha (TNF-alpha) | inflammatory bowel disease | development licensing commercialisation |
Inflammatory diseases - Gastrointestinal diseases | Licensing agreement |
